Profile Response Detail

Molecular Profile Unknown unknown
Therapy MK-1248 + Pembrolizumab
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable
Create By tyin
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable MK-1248 + Pembrolizumab Phase I Actionable In a Phase I trial, MK-1248 in combination with Keytruda (pembrolizumab) resulted in complete response in 6% (1/17) and partial response in 12% (2/17) of patients with advanced solid tumor (J Clin Oncol 36, 2018 (suppl; abstr 3029); NCT02553499). detail...
PubMed Id Reference Title Details
First-in-human phase 1 study of MK-1248, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody, as monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. Full reference...